The validity of giving adjuvant capecitabine after standard anthracycline and/or taxanes based neo-/adjuvant chemotherapy in early triple-negative breast cancer patients: An Egyptian prospective multicentric phase III trial
Background: Triple-negative breast cancer (TNBC) is considered an aggressive breast cancer subtype despite giving standard therapies, these patients have high metastatic and relapse rates in addition to short survival. Therefore, we conducted this trial to study the validity of giving adjuvant Capec...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
The Egyptian Association for Cancer Research (EACR)
2022-06-01
|
| Serie: | Egyptian Journal of Cancer and Biomedical Research |
| Soggetti: | |
| Accesso online: | https://jcbr.journals.ekb.eg/article_253126_e9d04975910274458f197ac6fbcb3f4a.pdf |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|